PER Postgame™: The Latest from Louisville 2022 – Utilizing Recent Data to Improve Care for Patients with Peanut Allergy
Released On
December 22, 2022
Expires On
December 22, 2023
Media Type
Internet
Completion Time
75 minutes
Specialty
Allergy, Immunology, Pediatrics, Primary Care
Topic(s)
Allergies, Anaphylaxis, New Drugs
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
This activity is supported by an educational grant from Aimmune Therapeutics, Inc.
Credit Available
- Physicians — maximum of 1.25 AMA PRA Category 1 Credits™
- Nurses — 1.25 Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity is directed toward allergists/immunologists, internists, pediatricians, NPs, PAs, and RNs. Other healthcare professionals involved in the management of patients with food allergy are invited to participate as well.
Activity Overview
Children with peanut allergies and their families often experience a profoundly reduced health-related quality of life. Data show that food allergy affects 4% to 7% of primary school children. A national allergy database demonstrated that peanut was the most common trigger among 105 cases of food-induced anaphylaxis. Living with peanut allergy can lead to fear and anxiety regarding the risk of exposure and reaction to the allergen.
The PER Postgame™ is an innovative and unique webcast by PER®. It is an in-depth, engaging data recap program, focusing on novel therapeutic agents and emerging treatment strategies discussed at major medical meetings. This program focuses on abstracts presented at the 2022 American College of Allergy, Asthma & Immunology (ACAAI) annual meeting.
Learning Objectives
- Upon completion of this activity, you should be better able to:
-
- Outline the quality-of-life (QoL)-related issues that patients with peanut allergies and their caregivers typically encounter
- Analyze recent efficacy and safety data of novel oral immunotherapy (OIT) agents that have the potential to substantially impact outcomes in patients with peanut allergies
- Design optimal treatment plans for toddlers with peanut allergies based on the latest clinical trial data findings regarding OIT agents
- Implement patient education and preferences in addition to important treatment considerations regarding OIT agents into shared decision-making (SDM) models while managing patients with peanut allergies
Faculty
Edwin H. Kim, MD MS
Associate Professor
Department of Pediatrics
University of North Carolina
Chapel Hill, NC
Carla M. Davis, MD
Professor of Pediatrics
Chief, Division of Immunology, Allergy, and Retrovirology
Director, Texas Children's Hospital Food Allergy Program
Janie and Sandra Queen Endowed Chair in Immunology and HIV/AIDS
Baylor College of Medicine
Texas Children's Hospital
Houston, TX
Julie Wang, MD
Professor, Department of Pediatrics, Jaffe Food Allergy Institute
Icahn School of Medicine at Mount Sinai
New York, NY
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.25 Contact Hours.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
- Edwin H. Kim, MD MS
-
- Grant/Research Support: NIH-NIAID, FARE
- Consultant: ALK, Allergy Therapeutics, Belhaven Biopharma, Kenota Health, Ukko, Nutricia, Genentech
- Carla M. Davis, MD
-
- Grant/Research Support: Regeneron, Allergenis, DBV, Takeda, Pfizer
- Consultant: Aimmune Therapeutics, Inc, Takeda.
- Julie Wang, MD
-
- Grant/Research Support: Aimmune, DBV, Regeneron, NIH, Siolta
- Consultant: ALK-Abello, Jubilant HollisterStier
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Instructions for Participation and Credit
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.